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Background: Osteoarthritis (OA) is a common joint disease that causes disabilities in elderly. However, few agents
with high efficacy and low side effects have been developed to treat OA. In this study, we evaluated the effects of
the alginate extract named CTX in OA cell and rabbit models.
Results: CTX was formulated by hydrolyzing sodium alginate polymers with alginate lyase and then mixing
with pectin. HPLC was used to analyze the CTX content. Human chondrosarcoma SW1353 cells treated with
interleukin-1β were used as OA model cells to investigate the effects of CTX on chondrocyte inflammation and
anabolism. CTX at concentrations up to 1000 μg/ml exerted low cytotoxicity. It inhibited the gene expression of
proinflammatory matrix metalloproteinases (MMPs) including MMP1, MMP3 and MMP13 in a dose-dependent manner
and increased the mRNA level of aggrecan, the major proteoglycan in articular cartilage, at 1000 μg/ml.
Thirteen-week-old New Zealand White rabbits underwent a surgical anterior cruciate ligament transection and were
orally treated with normal saline, glucosamine or CTX for up to 7 weeks. Examinations of the rabbit femur and tibia
samples demonstrated that the rabbits taking oral CTX at a dosage of 30 mg/kg/day suffered lesser degrees of articular
stiffness and histological cartilage damage than the control rabbits.
Conclusions: The gene expression profiles in the cell and the examinations done on the rabbit cartilage suggest that
the alginate extract CTX is a pharmaco-therapeutic agent applicable for OA therapy.
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Osteoarthritis (OA) is a gradually progressing disorder
affecting mammalian joints in which the articular cartil-
age and the surrounding extracellular matrix (ECM) are
destroyed [1, 2]. An imbalance between the repair and
degradation of the cartilage may disrupt the collagen
matrix, resulting in OA. The pathologic changes include
proteoglycan degradation, type II collagen degradation,
and eventually local or complete loss of the cartilage
matrix [3]. Cytokines and their downstream targets are
major players in the pathogenesis of OA [4, 5]. Pro-
inflammatory cytokines such as interleukin (IL)-1β are* Correspondence: yflin@tmu.edu.tw; chenchho@tmu.edu.tw
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drocytes and promotes the expression of several matrix
metalloproteinases (MMPs), including MMP-1, MMP-3,
and MMP-13 [6–8]. Many studies demonstrated that
chondrosarcoma SW1353 cells challenged with IL-1β
show similarities to primary human osteoarthritic chon-
drocytes [8–11]. IL-1β induces nuclear factor κ-B
(NFκB) as a common transcriptional regulator resulting
in a strong induction of those MMPs and the other cyto-
kine IL-6 in both SW1353 cells and primary human
chondrocytes. IL-1β-treated SW1353 cells can be of
value to serve as a model for OA.
The development of OA therapeutics focuses primarily
on disease-modifying OA drugs (DMOADs) and connect-
ive tissue structure-modifying agents (CTSMAs) [12–15].
Our team as well as others showed OA-relieving effects
of injectable hyaluronan, a polysaccharide and majordistributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
Table 1 Primer sequences for RT-PCR
Primer sequence
MMP-1
Forward: 5’-CCT TCT ACC CGG AAG TTG AG-3’
Reverse: 5’-TCC GTG TAG CAC ATT CTG TC-3’
MMP-3
Forward: 5’-GAA AGT CTG GGA AGA GGT GAC-3’
Reverse: 5’-AAC CGA GTC AGG TCT GTG AG-3’
MMP-13
Forward: 5’-GAA TTA AGG AGC ATG GCG AC-3’
Reverse: 5’-TAA GGA GTG GCC GAA CTC AT-3’
Aggrecan
Forward: 5’-TGA GGA GGG CTG GAA CAA GTA CC-3’
Reverse: 5’-GGA GGT GGT AAT TGC AGG GAA CA-3’
β-Actin
Forward: 5’-ACA CTG TGC CCA TCT ACG AG-3’
Reverse: 5’-TAC AGG TCT TTG CGG ATG TC-3’
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lasting therapeutic agent for OA [10, 16, 17]. A noninva-
sive dietary supplement of glucosamine has been used to
treat OA and is available clinically in some areas; however,
it may increase the risk of developing diabetes with high
dosages in long-term therapy [18]. Another polysacchar-
ide, alginate, is a potential OA therapeutic agent which
has also been studied in the form of injectable hydrogels
in cartilage regeneration [19, 20]. It would be worth inves-
tigating the effects of orally administered alginate.
Alginate is a family of natural polysaccharides distrib-
uted in the cell walls of algae. It has a great potential for
use in biomedical applications, especially in tissue engin-
eering because of its non-toxic nature, gentle sol/gel
transition procedure and low cost [21–24]. Moreover, al-
ginate oligosaccharides produced by enzymatic degrad-
ation of alginate polymers are also known to have several
biological activities including suppression of fibroblast
proliferation and collagen synthesis in human skin, stimu-
lation of endothelial cell growth and migration, stimula-
tion of human keratinocyte growth, and suppression of
Th2 development and IgE secretion [22, 25, 26]. ResultsTable 2 Macroscopic scoring parameters
Articular cartilage abnormality Score
0 1
Fissure None Very small
Osteophytes None Very small
Fibrillation None Noticeable
Ulceration None Mild
Loss of superficial layer Normal Slightsuggest that alginate is useful for the treatment of disor-
ders related to abnormal collagen metabolism such as OA.
Recent studies suggest that OA progression is associated
with biomarkers of synthesis, degradation and inflamma-
tion of collagen [27]; however, these markers are usually
nonspecific to OA. The severity of OA is clinically esti-
mated by radiation or magnetic resonance imaging. To
show pathological evidence on experimental animals,
macroscopic and histologic examinations are mostly used.
In this study, we hypothesize that the alginate extract
named CTX administered orally exerts alterative effects
in OA model cells and animals.
Methods
Preparation of the alginate extract CTX
An alginate oligosaccharide (oligomer) solution was ob-
tained by hydrolyzing sodium alginate polymers (~220
kDa) (Junsei Chemical Co., Japan) with alginate lyase
(Sigma Adrich, U.S.A.) in distilled water at 40 °C for
24 h. CTX was formulated by mixing the alginate oligo-
mers with pectin (Duksan Science, Korea) in a solution at
9:1 ratio and dried in a spray dryer. Alginate polymers and
oligomers were determined by an HPLC (Shimadzu
10AVP series) with Supelcogel-H column (Sigma Aldrich,
USA), and the procedure was modified from a protocol
described elsewhere [28]. Briefly, the column temperature
was 75 °C and the flow rate was 0.6 ml/min. Phosphoric
acid at 0.1 % as mobile phase along with a UV de-
tector wavelength at 210 nm were used for alginate
polymer analysis; deionized water as mobile phase
along with a refractive index detector were used for
alginate oligomer analysis. To determine the molecu-
lar weight, the formulated CTX was analyzed by gel
permeation chromatography with 0.1 M NaNO3 as
mobile phase in Shodex Asahipak GS-320/220 col-
umns at 35 °C.
Cell culture
The human chondrosarcoma SW1353 cell line was ob-
tained from the ATCC (American Type Culture Collection)
[9]. SW1353 cells were cultured in L-15 medium supple-
mented with 10 % fetal bovine serum (FBS) and 1 % L-glu-
tamine in a humidified incubator with 5 % CO2 at 37 °C.
Cells at 105/ml were pretreated with 0, 10, 100 or2 3 4
1 small 2 small or l large 3 small or 2 large
Small Medium Large
Moderate Marked Extensively severe
Moderate Focally severe Extensively severe
Moderate Focally severe Extensively severe
Table 3 Histopathological scoring parameters
Score Description
0 Normal matrix and chondrocytes
1 Uneven cartilage surface with loss of metachromasia around the
enlarged cartilage of superficial zone. No fibrillation chondrocyte
clusters
2 Some surface erosion, fibrillation and small chondrocyte clusters
in superficial zone decreased metachromasia extending to the
deep zone
3 Deeper surface erosion with fibrillation extending into the deep
zone, large number of chondrocyte clusters containing several
cells, major degenerative changes and loss of metachromasia in
the cartilage matrix
Fig. 1 The influence of CTX on SW1353 human chondrosarcoma cells. a Cell s
by an MTT assay. The relative density of surviving cells was normalized to the c
experiments were performed. b Effects of CTX on MMPs and aggrecan gene e
and aggrecan were examined by RT-PCR and agarose gel electrophoresis (left
from IL-1β-induced cells were plotted, and CTX-treated results were normalized
three independent sets of experiments. **p < 0.01
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recombinant human IL-1β (R&D Systems Inc.) for up to
24 h. The cells were then collected and analyzed as
indicated.
Cell viability assay
SW1353 cells were cultured in 24-well flat-bottomed
tissue culture plates and treated with 0, 10, 100 or
1000 μg/ml CTX (sterilized with 0.22 μm filter) for 24 h.
After incubation, the medium was replaced with 100 μl of
a mixture of a ratio of 1:9 composing MTT (3-[4,5-di-
methylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) and
medium. Cells were then incubated for 2 h and analyzed
at an absorbance of 550 nm. The rate of tetrazolium re-
duction is proportional to the cell number.urvival at various concentrations of CTX. The surviving cells were detected
ontrol group, which was set as 100 %. Four independent sets of
xpression in the cells. The gene expression of MMP-1, MMP-3, MMP-13
panel). The density of β-actin was used as the loading control. The results
to the control (right panel). Data were expressed as the mean ± SE from
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Cells were preincubated with 0, 10, 100 or 1000 μg/ml
CTX for 30 min. To model OA pathogenesis, a set of cells
was stimulated with 5 ng/ml IL-1β for 6 h. Total RNA
was extracted (TRIzol) from chondrosarcoma cells. The
RNAs (1 μg) were reversely transcribed into cDNAs using
oligo-dT primers and GoScript™ Reverse Transcription
System (Promega, life sciences). The presence of MMPs,
Aggrecan and β-Actin mRNA in cells were analyzed by
PCR and agarose gel electrophoresis as described [10].
The results of each sample were normalized to β-actin.
Primer sequences are listed in Table 1.
Animals
Thirteen-week-old New Zealand White male rabbits
with mature skeletons were used as the experimental
OA animals. The animals were kept in steel cages (35 ×
53 × 35 cm) (W × D × H) individually at 22 ± 3 °C and
55 ± 20 % humidity. Animals were fed RC4 pellet-type
laboratory-animal food. There was no extra calcium sup-
plied, and tap water was given freely. All animal proce-
dures were approved by the Institutional Animal Care
and Use Committee at Taipei Medical University.Experimental OA model
Rabbits were divided into five groups of ten each. Four
groups were experimental OA-induced animals prepared
according to the protocol of an anterior cruciate ligment
transection (ACLT) [29]. The rabbits were anesthetized
using a combination of Zoletil (Tiletamine + Zolezepam)
(Zoletil-Virbac, Carros, France) and Rompun (Bayer,
Leverkusen, Germany). Their right knee joints were in-
cised aseptically two cm down the lateral aspect of the
patella to expose and cut the anterior cruciate ligment.
The subdermal muscular layer and skin was sewn by
knotting absorbable and nylon sutures. Antibiotics were
applied subcutaneously near the thigh.
The group that did not undergo the ACLT procedure
(normal) and one group with ACLT were fed normal sa-
line to serve as controls. The other three groups were
fed either glucosamine (10 mg/kg/day) or CTX (10 or
30 mg/kg/day). All agents were administered orally from
the first day of the ACLT procedure to 7 weeks.Fig. 2 Pain assessment on experimental OA rabbits with different
treatments. The rabbits were orally treated with normal saline,
glucosamine or CTX as described in Methods. The percentage (%)
weight distribution of the experimental right hind paw was
calculated as mean ± SD from 10 animals in each groupPain assessment
The experimental OA rabbits were orally treated with nor-
mal saline (10 mg/kg/day), glucosamine (10 mg/kg/day) or
CTX (10 or 30 mg/kg/day). Both hind paws of the rabbits
were weighed the day before the surgery and weekly up to
seven weeks after the surgery. The percent (%) weight dis-
tribution of the experimental right hind paw was calcu-
lated as described [17, 30].Specimen collection
After the rabbits were euthanized, knee joint specimens
were collected by osteotomy 3 cm above and below the
joints and fixed in 10 % buffered formalin (pH 7.4) for
24 h. Fixed specimens were cleared of soft tissues and
ligaments allowing the gross examination of the articular
surfaces of the femoral condyles and tibial plateaus.Macroscopic examination
The macroscopic examination of the specimens was per-
formed using a surgical magnifying glass to evaluate the
OA progression based on a modification of the parame-
ters described previously [31] and is summarized in
Table 2. The presence of fissures (V-shaped cleft), osteo-
phytes/chondrocytes, fibrillation (surface fragmentation),
cartilage ulceration (erosion), and the loss of the superfi-
cial layer were evaluated based on the location, type, and
size of the pathological features. All the samples were
blindly examined. Digital photographs of the articular
surfaces were taken.Histological (microscopic) examination
The histological examination was performed at the fem-
oral condyle of the rabbits. The specimens were fixed in
10 % formalin (pH 7.4) containing 0.5 % cetylpyridinium
chloride and sectioned. After decalcification, the speci-
mens were stained with hematoxyline and eosin (H&E)
and Alcian blue separately. The pathological scoring pa-
rameters are listed in Table 3 and used to evaluate the se-
verity of OA on a scale of 0 to 3. The average score of all
the sites represented the OA severity of an animal.
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At least three independent sets of experiment were per-
formed. Results were analyzed using SigmaPlot 12.5 soft-
ware. Statistical analysis was done with Student’s t test
and one way ANOVA. Differences were considered sig-
nificant if p < 0.05 (*) or 0.01 (**).
Results
CTX inverted OA pathogenesis in vitro
After the lyase hydrolyzation alginate polymers were
converted into oligomers. The average molecular weight
of the hydrolyzed product CTX was estimated 2,550
Dalton. Chondrosarcoma SW1353 cells were tested with
different concentrations of the alginate extract CTX.Fig. 3 Macroscopic examination of the tibia and femur of OA rabbits. a Th
condyle (under) of the five groups of rabbits. Normal, control (no surgery);
10 mg/ka/day glucosamine; CTX 10, treated 10 mg/kg/day CTX; CTX 30, tre
was conducted as described in Methods and Table 2. The five evaluated ite
chondrocytes, fibrillation (surface fragmentation), ulceration (erosion), and l
examined. The results were compared to the group of normal saline-treateTheir viabilities were not noticeably affected by CTX at
concentrations up to 1000 μg/ml in 24 h (Fig. 1a), sug-
gesting a satisfactory safety of CTX to be investigated in
cellular anabolism.
When the OA model cells were treated with CTX for
6 h, their mRNA expressions of MMP-1, MMP-3,
MMP-13 and aggrecan were analyzed using RT-PCR. As
expected, IL-1β induced mRNA levels of the MMPs in
the cells (Fig. 1b). CTX reduced their expressions in a
dose-dependent manner with a significant difference at
100 μg/ml for MMP3 and MMP13 and 1000 μg/ml for
all the MMPs, suggesting an anti-inflammatory effect of
the agent. Furthermore aggrecan, the major proteoglycan
found in the articular cartilage [32], was dramaticallye surface appearance of the tibial plateau (over) and the femoral
Saline, treated 10 mg/ka/day normal saline; glucosamine, treated
ated 30 mg/kg/day CTX. b The macroscopic appearance assessment
ms include the presence of fissure (V-shaped cleft), osteophytes/
oss of superficial layer. At least three animals in each group were
d animals. * p < 0.05
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acting effect of CTX on OA pathogenesis.
Animals recovered from OA with oral CTX
The surgery-induced OA rabbits that underwent differ-
ent treatments were monitored for pain on the experi-
mental right hind paw. The percent weight distribution
on the right hind paw was largely reduced in all the OA
rabbit groups, indicating a pain on their joints (Fig. 2).
The pain was relieved gradually with time. Although no
treatments including glucosamine and CTX exhibited
analgesic activity significantly, the tissue repair may be
processed differentially among these treatments.
The macroscopic examination of the specimens showed
that the experimental OA articular cartilage was rough
and dull on both femoral and tibial surfaces of the control
rabbits (Fig. 3a). The most remarkable damage occurred
at the femoral condyle and the tibial plateau. Glucosamine
and CTX at 10 mg/kg/day were shown to be not effective.Fig. 4 Histological examinations of cartilage at the femoral condyle. The sp
Alcian blue (b) as described in Methods. Normal, control (no surgery); Salin
day glucosamine; CTX 10, treated 10 mg/kg/day CTX; CTX 30, treated 30 m
Methods and Table 3. The mean ± SD was calculated based on the scoresThe OA groups, except for the one treated with 30 mg/
kg/day CTX, displayed uneven articular surfaces with se-
vere loss of articular cartilage. Generally, however, OA
rabbits treated with CTX at 30 mg/kg/day showed im-
proved cartilage repair with significantly lower scores of
fissures and ulceration (Fig 3b). An even articular surface
with regeneration of cartilaginous tissue was also ob-
served. Thus, it is assumed that CTX inverted the progres-
sion of OA.
OA tissue repaired with CTX treatment
The microscopic histological examination showed the
damaged femoral condyles stained with H&E and alcian
blue separately from the OA rabbits (Fig. 4a and b). There
were marked cleft changes, articular cartilage proteoglycan
loss, fibrosis and cleft formation with more subchondral
sclerosing bone formation. Oral CTX at 30 mg/kg/day at-
tenuated lesion formation with signs of restoration of the
cartilage structure significantly (Fig. 4c). An even articularecimens were stained with hematoxyline and eosin (H&E) (a) and
e, treated 10 mg/ka/day normal saline; glucosamine, treated 10 mg/ka/
g/kg/day CTX. c Histopathological scores were given as described in
of three or more animals in each group. * p < 0.05
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ticed. Overall, the treatment with CTX at 30 mg/kg/day
resulted in the best improvement from OA.
Discussion
In our study, alginate extracted CTX was suggested as a
potential agent to promote matrix anabolism and stimu-
lated cartilage regeneration. In the OA model cells, we
found an effective treatment of CTX at 1000 μg/ml in
reducing MMPs and promoting aggrecan expression al-
though the effects were not obvious at low CTX (Fig. 1b).
Aggrecan is important for cartilage elasticity, toughness
and shock-absorbing capacity. Its degradation is a sig-
nificant event in the early-stage OA [33]. Indeed, CTX
improved cartilage structure restoration although it did
not serve as an analgesic in the OA model rabbits (Figs. 3
and 4). Based on our data, we suggest that the CTX pro-
vide therapeutic effects for OA.
Although the etiology of OA is still intensively de-
bated, its pathological features are well established. OA
is composed by a group of overlapping distinct diseases,
which may have different etiologies with similar biologic,
morphologic, and clinical outcomes. The disease not
only affects the articular cartilage, but also involves the
entire joint, including the subchondral bone, ligaments,
capsule, synovial membrane, and periarticular muscles
[34]. Ultimately, the articular cartilage degenerates with
fibrillation, fissures, ulceration, and loss of the joint sur-
face. Studies showed hydrogel-based alginate possesses
high viscosity and viscoelasticity which may provide
good chondro-protective effects [35]. The mechanism
how orally administered alginate exerts its function in
articular cartilage is not known; however, our results
suggest that CTX can prevent joint abrasion in early
stages of OA. The digested alginate could be trans-
formed into other glycans of the cartilage.
The group treated with 10 mg/kg/day CTX displayed
an increase in fissures and osteophytes/chondrocytes
(Fig. 3). This may suggest an on-going process of a feed-
back phenomenon, in which a greater amount of chondro-
cytes are recruited for the production of proteoglycan.
CTX can increase aggrecan and decrease the MMPs
production in chondrocytes (Fig. 1b). As erosion and
loss of cartilage occurred, the remaining chondrocytes
secreted more glycoprotein for bone regeneration,
resulting in the production of osteophytes [17]. Thus,
CTX represents an ideal DMOAD and CTSMA; how-
ever, its long-term therapeutic effects on chronic OA
may need further investigation.
Conclusions
The alginate extract CTX was found to invert OA
pathogenesis in vitro by increasing aggrecan anddecreasing MMPs production in the cells. It also
exerted a beneficial ability in vivo by promoting re-
generation of cartilaginous tissue. Therefore, CTX
may be used in OA therapy.
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